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S U M M A R Y
Objectives: To determine risk factors in children for the acquisition of Brucella, clinical presentation,
treatment, and disease outcomes.
Methods: A retrospective multicenter chart review was undertaken of children identiﬁed with
brucellosis from 1986 to 2008 at three tertiary care centers in Chicago, Illinois, USA. The charts were
reviewed for data regarding risk factors for acquisition, clinical presentation, and outcomes.
Results: Twenty-one charts were available for review. The median age was 6.5 years (range 2–14 years);
62% were female. Ethnic background was 67% Hispanic and 24% Arabic. Risk factors included travel to an
endemic area (86%), particularly Mexico, and consumption of unpasteurized milk products (76%).
Common ﬁndings included fever (95%), bacteremia (86%), elevated liver transaminases (80%),
constitutional symptoms (76%), splenomegaly (60%), and hepatomegaly (55%). Relapse occurred in
three of six subjects started on single drug treatment, but in only one of 15 subjects who started on two
or more drugs (p = 0.053). No relapses occurred in children whose initial therapy included rifampin or
those administered three-drug regimens.
Conclusions: Brucella is an infrequent pathogen but should be considered in children with compatible
epidemiologic and clinical characteristics. Blood cultures should be obtained, and initial therapy with
two or more drugs may decrease the risk of relapse.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Brucellosis is a zoonotic disease of wild and domestic animals
caused by bacteria of the genus Brucella. Humans typically contract
disease by accidentally ingesting contaminated food, such as
unpasteurized milk products, but can also acquire it through
inoculation via direct contact with infected animals or animal parts
and occasionally through occupational exposure in microbiology
laboratories.1–3
Brucella remains a rare disease in the USA, with approximately
100–200 cases reported per year, generally found in travellers
returning from high-risk areas.4–7 Surveillance data suggest that
brucellosis occurs at a rate eight-fold higher in counties within
100 km of the border with Mexico than in states that do not
border Mexico.8 Of the 121 individual cases of brucellosis reported
in 2006, 43% occurred in Texas or California, while 6.7% occurred in§ An earlier version of this manuscript was presented as a poster at the Infectious
Diseases Society of America Annual Meeting in Vancouver, BC, Canada, October
2010.
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doi:10.1016/j.ijid.2011.08.002Illinois.9 Studies from Texas and California suggest that 79–95% of
disease occurs among Hispanics in these states.4–6
Also known as undulant fever, the recurrent fever episodes in
brucellosis characteristically rise and fall in waves, with high
spikes often accompanied by rigors or chills.10 In humans, the
manifestations are protean and include myalgias, arthralgias,
hepatitis, lymphadenopathy, hepatomegaly, splenomegaly,
osteoarticular involvement such as sacroiliitis, peripheral arthritis,
or spondylitis, and less commonly uveitis, central nervous system
disease, or endocarditis, and is most commonly due to Brucella
melitensis.11–14 The disease left untreated can be severely
debilitating and is associated with long-term morbidity.
Recent large series data about brucellosis in the USA are
restricted to states neighboring Mexico.4–6,15 Our understanding of
pediatric brucellosis in the USA is particularly limited, prompting
us to review our experiences at multiple different academic
institutions in Chicago over the past 23 years.
2. Methods
A multicenter retrospective chart review was conducted at
three large tertiary care centers in Chicago, Illinois: Rush
University Medical Center, John H. Stroger Jr. Hospital of Cookses. Published by Elsevier Ltd. All rights reserved.
Table 1
Demographics and epidemiological risk factors of children with brucellosis
Patient Age (years) Sex Race/ethnicity Region of travel outside
USA/residence prior to illness
Presumed exposure source Time to symptom onset
after exposure (months)a
1 10 Female Hispanic Mexico Unpasteurized milk products 9
2 4.5 Female Caucasian None Direct animal contact (goats) 2
3 4.5 Male Arabic Lebanon Unpasteurized milk products <1
4 5 Male Arabic Jordan, Israel Unpasteurized milk products <1
5 6.5 Male Arabic Jordan, Israel Unpasteurized milk products <1
6 3 Male Arabic Jordan, Israel Unpasteurized milk products <1
7 4.5 Female Arabic Jordan, Israel Unpasteurized milk products <1
8 6.5 Male Hispanic Mexico Unpasteurized milk products 1
9 10 Female Hispanic Peru Unpasteurized milk products 1
10 14 Male Hispanic Mexico Unpasteurized milk products 3
11 12 Female Hispanic Mexico Unpasteurized milk products 3
12 3.5 Female Hispanic Mexico Unknown NA
13 3.5 Female Hispanic Mexico Unpasteurized milk products 4
14 8 Female Hispanic Mexico Unknown NA
15 6.5 Male Hispanic Mexico Unpasteurized milk products <1
16 12 Female Hispanic None Unpasteurized milk products 3
17 2 Female Hispanic None Unpasteurized milk products 1
18 14 Female Hispanic Mexico Direct animal contact (goats) <1
19 13 Female Hispanic Mexico Unpasteurized milk products <1
20 5 Male Hispanic Mexico Unpasteurized milk products <1
21 10.5 Female Asian Pakistan Unknown NA
a NA, not applicable; <1, symptom onset within 4 weeks after exposure.
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approved by the institutional review boards of the three
institutions. Cases of Brucella occurring in children <18 years of
age during the period of January 1, 1986 to December 31, 2008
were identiﬁed by searchable electronic inpatient and outpatient
databases of International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation (ICD-9-CM) code 023 (023.0–
023.9). A case was deﬁned based on veriﬁcation of clinical and
laboratory supported evidence of brucellosis. Conﬁrmed diagnosis
was based on isolation of Brucella species on cultures of blood, bone
marrow, cerebrospinal ﬂuid, other sterile sites, or in tissue
samples. The Illinois Department of Public Health and/or Centers
for Disease Control and Prevention were sent all positive cultures
for conﬁrmation and speciation. A single positive Brucella serum
agglutination titer (SAT) of 1:160 was also considered deﬁnite
evidence of infection when accompanied by compatible clinical
evidence of disease in the absence of a positive culture.
Length of bacteremia was deﬁned by number of days between
ﬁrst and last positive blood culture during therapy. Treatment
failures were deﬁned as persistent positive blood cultures or
persistence of symptoms after 10 days of therapy.16 Relapse was
deﬁned as recurrence of symptoms or blood culture positivity after
completion of therapy. p-Values were determined using the
Fisher’s exact test in comparing those who had a relapse with
those who did not have a relapse. Charts were reviewed for
evidence of a relapse of brucellosis for at least 2 years after initial
hospital discharge.
3. Results
3.1. Patient demographics
Twenty-one charts were available for review of the 22
conﬁrmed cases (95%) of childhood brucellosis from 1986 to
2008 (Table 1). Of the subjects available for analysis, the median
age was 6.5 years (range 2–14 years); 13 (62%) were female and
eight (38%) were male. Fourteen (67%) were Hispanic, while ﬁve
(24%) were Arabic. Eighteen (86%) reported recent travel or
residence in an endemic country, with 11 (52%) having been in
Mexico. Sixteen (76%) had a history of consumption of raw or
unpasteurized milk products, two (10%) had had direct contact
with goats, and in three (14%) no exposure history was described.Eight (38%) subjects had another family member with brucellosis,
including four subjects (Table 1, Subjects 4–7) who were all
identiﬁed from the same family.
3.2. Clinical signs and symptoms
The median time to symptom onset after the presumed
exposure was 0.5 months (range 0–9 months). Clinical symptoms
on presentation were widely variable in children (Table 2).
Subjective fever, present in 20 (95%) children was the most
common presenting symptom. The one child without fever was on
corticosteroids at the time of presentation. Seventy-six percent
had constitutional symptoms, 24% reported abdominal pain, and
24% vomiting and/or diarrhea.
Records of clinical signs on presentation were available for 20 of
the children (Table 2). Clinical ﬁndings included splenomegaly in
60%, hepatomegaly in 55%, arthritis in 35%, central nervous system
(CNS) in 15%, osteomyelitis in 10%, and cardiac in 10%. The arthritis
was typically monoarticular, and most commonly involved the
sacroiliac, knee, and hip joints. The two cases of osteomyelitis
occurred in the iliac bone and femoral head. Two children with CNS
symptoms had cerebrospinal ﬂuid pleocytosis with negative
cultures, one of whom also had left-sided weakness, facial droop,
left upgoing toes, and a normal contrast enhanced computerized
tomography scan. A third child had uveitis. Serology of spinal ﬂuid
was not performed. Cardiac ﬁndings included a right bundle
branch block in one child associated with bradycardia. A small
pericardial effusion and mild mitral regurgitation associated with
mild left atrial dilatation was observed in a second child. No
children were identiﬁed as having endocarditis.
3.3. Laboratory ﬁndings
Twenty children had laboratory records available for review
(Table 3). The most common ﬁnding was elevated transaminases in
16 (80%). Anemia occurred in 13 (65%). Seventeen initial platelet
counts were available; the median platelet count was normal at
224  109/l (range 35–530  109/l), however ﬁve (29%) had
platelet counts <150  109/l, two of which were <100  109/l.
Two patients had pancytopenia. The erythrocyte sedimentation
rate was available on presentation in 15 children, with a median of
46 mm/h (range 8–82 mm/h).
Table 2
Clinical symptoms and signs in children with brucellosis
Symptoms (data available for 21 patients) No. (%)
Fever 20 (95)
Constitutional symptomsa 16 (76)
Anorexia 10 (48)
Fatigue 7 (33)
Chills 5 (24)
Weight loss 5 (24)
Myalgias/arthralgias 5 (24)
Abdominal pain 5 (24)
Vomiting and/or diarrhea 5 (24)
Sore throat 4 (19)
Neuropsychiatricb 2 (10)
Otherc 6 (29)
Physical signs (data available for 20 patients) No. (%)
Splenomegaly 12 (60)
Hepatomegaly 11 (55)
Arthritis 7 (35)
Sacroiliac 3 (15)
Knee 2 (10)
Hip 2 (10)
Central nervous system 3 (15)
Osteomyelitis 2 (10)
Cardiac 2 (10)
Mesenteric adenitis 1 (5)
a Constitutional symptoms include anorexia, fatigue, chills, weight loss,
myalgias/arthralgias.
b Neuropsychiatric symptoms include withdrawn, sad, or depressed.
c Other includes headache, rash, epistaxis, constipation.
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cultures in 18 (86%), however the initial diagnosis was made by
blood or bone marrow culture in 11 (52%) and by serology in 10
(48%). The median length of bacteremia was 2.5 days (range 1–67
days) and the median number of positive blood cultures was two
(range 1–5). In three children (14%), the diagnosis was dependent
on serology because of negative blood cultures. Brucella SAT was
available in 15 children and the median was 1:320 (range 1:160–
1:2580). Conﬁrmation of Brucella species was available in six of the
cases and all were identiﬁed as B. melitensis.Table 3
Laboratory ﬁndings in children with brucellosisa
Laboratory ﬁnding No. (%) Median (range)
Elevated transaminases 16 (80)
White blood count
Normal 13 (65) 7150 (2600–14500)
Low 6 (30)
High 1 (5)
Hemoglobin (g/dl) 10 (6.8–13.6)
Anemia 13 (65)
Platelets ( 109/l)a 224 (35–530)
Thrombocytopenia 5 (29)
<100 2 (12)
Pancytopenia 2 (10)
Elevated ESR (mm/h)a 13 (87) 46 (8–82)
Positive blood or bone marrow cultures 18 (86)
Length of bacteremia (days) 2.5 (1–67)
Positive blood cultures per patient 2 (1–5)
Brucella melitensis 6 (100)
Brucella serum agglutination test (SAT)b 15 (71) 1:320 (1:160–1:2580)
ESR, erythrocyte sedimentation rate.
a Data were available for 20 patients, except platelet counts available for 17 and
ESR available for 15.
b Fifteen (71%) children had a SAT performed; 100% had a positive test result.3.4. Treatment and outcomes
The initial treatment regimens varied considerably and are
listed in Table 4 along with relapse rates and outcomes. The
median length of antibiotic therapy was 6 weeks (range 2–22
weeks). The most commonly used initial antibiotic therapy was
trimethoprim–sulfamethoxazole (TMP–SMX) in ﬁve (24%) as
single drug therapy, though it was also included in seven (33%)
combination regimens. A tetracycline derivative (tetracycline or
doxycycline) was used as single drug therapy in one (4.8%) patient
and was included in seven (33%) combination regimens. Combi-
nation regimens consisted of two- or three-drug therapy, which
included rifampin in 10 (48%) and an aminoglycoside (streptomy-
cin or gentamicin) in 11 (52%). One patient had a signiﬁcant
complication of antibiotic therapy, which was a secondarily
infected peripherally inserted central catheter.
Relapse occurred in four (19%) children with recurrence of
presenting symptoms and/or positive blood cultures after com-
pletion of therapy. Treatment failure occurred in two (10%)
children with recurrence of symptoms while on therapy and/or
persistent positive blood cultures. Three of six subjects started on a
single drug for Brucella relapsed, but only one of 15 subjects who
were started on two or more drugs (p = 0.053). All children
experiencing treatment failure or relapse were on single or two-
drug combination regimens that did not initially include rifampin.
All such children were rehospitalized and retreated with two- or
three-drug combinations that included rifampin and were cured.
All relapses occurred within the ﬁrst 4 months after therapy was
completed, and treatment failure occurred within 2 weeks of
initiation of therapy. Two additional children who were labeled as
chronic brucellosis (arthritis) on presentation were initially
treated in Mexico, but had had no symptom-free interval between
presentations. The outcome of children was good, with 15%
requiring initial intensive care monitoring, successful cure in all
cases of relapse, and no mortality within 2 years of presentation.
4. Discussion
Brucellosis is the most common zoonotic disease worldwide,
accounting for over 500 000 infections each year.17 Worldwide, B.
melitensis is the most common cause of infection, and in endemic
areas such as the Middle East, is associated with direct contact with
infected animal parts and the consumption of unpasteurized milk
products; several animal species may be sources, including camels,
goats, and sheep.18 In the USA only 100–200 cases occur annually
due to the pasteurization of milk products and vaccine eradication
campaigns in livestock; the disease is most commonly seen in
states that border Mexico.4–7,15,19 In recent studies, most
brucellosis has been observed in the Hispanic population and
has been associated with travel to and/or consumption of
unpasteurized milk products from Mexico.4–6 However, endemic
brucellosis still remains in the USA; Brucella abortus-affected cattle
herds, associated with free ranging elk and bison, continue to be
reported in the state of Montana, and Brucella suis disease has been
associated with feral swine hunting.20,21
Most epidemiologic studies have come from endemic countries
where prevalence is highest in the 15–35 years age group.14 In the
USA, recent Centers for Disease Control and Prevention (CDC) data
demonstrate brucellosis to be associated with male and Hispanic
predominance, with 57% of cases occurring in the 25–64 years age
group, and only 17% occurring in children aged 0–14 years.22 In
California and Texas where reports of brucellosis are most
common, the age distribution is similar to endemic countries,
predominating in the 20–49 years age group.4,15
A brief summary of 2005 Illinois brucellosis cases found the
median age of brucellosis patients to be 44 years.23,24 The last prior
Table 4
Therapeutic regimens and outcomes in children with brucellosis
Patient Initial antibiotic regimen Duration of therapy (weeks) Relapse or treatment failure
1 TMP–SMX 3 Relapse
2 TMP–SMX 2 Relapse
3 TMP–SMX 3 No
4 TMP–SMX 3 No
5 TMP–SMX 2 No
6 TET 6 Relapse
7 TMP–SMX + G 22 Treatment failure and relapse
8 TMP–SMX + G 6 Treatment failure
9 TET + G 3 No
10 DOXY + G 3 No
11 TET + S 4.5 No
12 TMP–SMX + RIF 8 No
13 TMP–SMX + RIF 6 No
14 TMP–SMX + RIF 6 No
15 TET + RIF 6 No
16 TMP–SMX + G + RIF 6 No
17 TMP–SMX + G + RIF 6 No
18 TMP–SMX + G + RIF 6 No
19 DOXY + G + RIF 6 No
20 DOXY + G + RIF 6 No
21 DOXY + G + RIF 6 No
TMP–SMX, trimethoprim–sulfamethoxazole; R, rifampin; S, streptomycin; G, gentamicin; TET, tetracycline; DOXY, doxycycline.
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that brucellosis was primarily an endemic disease of livestock
handlers; now, it is primarily a disease of immigrants or travelers
to endemic areas.23,24 Consistent also in most recent US reports is
an overwhelming predominance of disease within Hispanic
immigrants from Mexico.4,15 Illinois has consistently been the
state with the third highest number of cases in the USA, but a
recent large review of cases from the Midwest has not been
published.9,23 Similarly, US data regarding brucellosis in children
are very limited. A Medline search of child and brucellosis, limited
to the English language between the years of 1950 and 2010
produced 576 articles, 31 of which were from the USA and having
some reference to children, and of which the largest prior pediatric
brucellosis series was 20 cases from Texas.6
Data from the 2010 US Census of metropolitan Chicago reveal a
racial/ethnic distribution of 42% White, 37% Black, 26% Hispanic/
Latino (of any race), and 4% Asian.25 The foreign-born population in
Illinois has dramatically increased, rising 86% between 1990 and
2006, and Illinois ranks among the top six states for new
immigrants. Of these immigrant populations, approximately half
of all immigrants to metropolitan Chicago were from Latin
America, nearly a quarter from Asia, and approximately 10% from
Poland.26 Additionally, the most recent data from the 2000 US
Census show that 24% of people who reported Arab ancestry lived
in the Midwest.27 In our study of pediatric brucellosis, 67% were
Hispanic, similar to other studies,4–6,15 however approximately
one-quarter of our population were immigrants of Middle-eastern
descent, which reﬂects the diversity of our local population and a
single family cluster. Imported infectious disease processes often
reﬂect immigration patterns and, as these are constantly evolving,
new diseases may emerge or old diseases reemerge based on these
local patterns. Clinicians therefore need to be aware of local human
migration patterns and these often forgotten diseases.
Once Brucella invades the mucosa, it internalizes and evades
killing within phagocytes, allowing bacteria to replicate and spread
through the blood and reticuloendothelial system.28,29 The
incubation period is highly variable and can range from less than
1 week to several months, with symptom onset generally 2–4
weeks after exposure.7,30 The ﬁnding of bacteremia in the majority
(86%) of our patients is consistent with other reviews of childhood
brucellosis, and is particularly associated with B. melitensis.31,32
Prior to the advent of automated continuous monitoring blood
culture systems such as the BACTEC system (Becton Dickinson,Franklin Lakes, NJ, USA), Brucella could take several weeks to grow
in culture and most cases were diagnosed with serology. Though
we were unable to determine time to positivity in our retrospective
review, other studies have suggested that the diagnosis can now be
made utilizing this system in less than 7 days.33 The ﬁnding of a
relatively short median incubation period of 0.5 months is
consistent with a history of travel to endemic areas. The nature
of the variation in range of incubation of 0–9 months in our
population is difﬁcult to assess due to the retrospective nature of
the study, however reexposure in those residing in endemic areas
prior to relocating to the USA could explain prolonged incuba-
tions.22
Signs and symptoms in our patients are consistent with other
pediatric reviews. Fever and constitutional symptoms consisting of
chills, sweating, fatigue, malaise, anorexia, weight loss, abdominal
pain, headaches, myalgias, and arthralgias, are amongst the most
common complaints in children.31,34 In the present study, fever and
constitutional symptoms were exhibited in 95% and 76% of children,
respectively. The hematologic ﬁndings of brucellosis often reveal a
normal white cell count, with mild anemia and decreased platelets,
though pancytopenia in the epidemiologic context should raise
suspicion of this diagnosis.35 Liver involvement of hepatomegaly
and splenomegaly with mild to moderate liver transaminase
elevations are also common complaints of children with brucellosis,
with rates of organomegaly of between 6% and 51% reported in
recent studies from endemic areas31,34,36,37 and 40% in recent US
studies.6 We found even higher rates of organomegaly in our
population, of 55% hepatomegaly and 60% splenomegaly.
Complications were also typical in our children, consistent with
previous reviews in which monoarticular arthritis of the knee,
sacroiliac, and hip joints are most commonly described.6,31,34,36–38
The largest prior US pediatric review found 50% of children with
arthritis on initial presentation, which is higher than, but
consistent with our ﬁnding of arthritis in 35% of cases.6 The
presentation of fever and arthritis, particularly of the knee and hip,
could be confused with more common causes of pyogenic arthritis
in children, however the prolonged length of fever, subacute
presentation, and lower median leukocyte counts in synovial ﬂuid
may be useful for distinguishing Brucella from acute pyogenic
organisms.39
The protean manifestations of brucellosis can be highlighted in
children. Some of the less common but noteworthy complications
of brucellosis are CNS and cardiac disease. Two of the children in our
L.K. Logan et al. / International Journal of Infectious Diseases 15 (2011) e812–e817e816population were described as depressed or withdrawn, consistent
with neuropsychiatric symptoms of brucellosis previously de-
scribed in the literature.12,40 Common cardiac complications are
endocarditis followed by myocarditis.13,41 We had two children in
our study with cardiac complications, one of whom had bradycardia
associated with a right bundle branch block without evidence of
valvular disease, which is an uncommon ﬁnding. Cardiac ﬁndings
were presumed to be related to brucellosis as none of the children
had a prior history of cardiac disease, symptom onset appeared to be
temporally related to infection, and resolution of symptoms
occurred in all cases once Brucella active treatment was initiated.
Changes have occurred in the antibiotic management of
Brucella over time. The treatment regimens in our pediatric
population were highly variable, which likely reﬂects the long
study duration and conﬂicting evidence for ideal therapy in
children. In adults, tetracyclines are recommended for therapy, but
this antibiotic class is typically avoided in children aged 8 years
due to the risk of dental staining. The two largest prospective trials
of therapy in children showed that combination therapy with
trimethoprim–sulfamethoxazole and rifampin, with or without
aminoglycoside therapy, can be associated with high cure rates
and outcomes.42,43 The optimal duration of therapy remains
unclear, though treatment of less than 45 days may be associated
with higher relapse rates.42,44–46
Our study had a relapse rate of 19%, which is similar to that of
other recent reported relapse rates in children of 0–25%.6,31,34–38
Early antibiotic regimens utilizing single drug therapy have been
found to be less efﬁcacious than the current recommendations of
combination therapy involving two or more medications active
against Brucella.7,28 Our data would support this in that relapse
occurred in three of six subjects started on a single drug for
Brucella but in only one of 15 subjects who started on two or more
drugs (p = 0.053). Notably, no relapses occurred in children whose
initial therapy included rifampin or those administered three-drug
regimens (which always included an aminoglycoside), but the
numbers were small. All children in our study with relapses were
cured upon retreatment and all children recovered.
Our study has several limitations. Methodological limitations
include a retrospective study design and a small cohort of patients
which allows for potential selection bias; however, because the
study was multicenter, it potentially lessens this bias. Second, our
deﬁnition of treatment failure was arbitrary as there is no evidence-
based deﬁnition in the literature, but was quite similar to another
study.16 Third, information on risk factors may potentially be
incomplete as this was a retrospective chart review, however
potential risk factors were found in all but three children. Finally,
since we were comparing treatment and outcomes over different
time periods, which can be prejudiced by confounding factors, we
can only postulate that the use of two- or three-drug combination
therapy may result in better outcomes for children with brucellosis.
In conclusion, childhood brucellosis in the USA is associated with
travel or residence in endemic regions and the consumption of
unpasteurized milk products. Most children are bacteremic,
presenting with prolonged fever, constitutional symptoms, mono-
articular arthritis, hepatomegaly and/or splenomegaly. Common
laboratory ﬁndings include mild anemia and mild to moderate
elevations in liver transaminases. In the Midwestern USA, ethnic
demographics of children with Brucella may represent the diversity
of immigrants to the region. The use of two- or three-drug
combination regimens for treatment in children may result in
lower relapse rates.
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